Most important breast cancer drug in two decades will not get NHS funding

Most important breast cancer drug in two decades will not get NHS funding A new drug described as one of the "most important" advances in treating breast cancer in two decades will not be approved on the NHS, under rationing plans.
Around 6,000 women a year, many with terminal disease, could benefit from palbociclib. The treatment has been found to stall tumours by 10 months - almost twice as long as standard drugs.
But the National Institute for Health and Care Excellence (Nice) said the cost – at around £3,000 a month – was too high, and that clinical trials were unclear about whether the drug improved overall survival. The Telegraph